Holen Sie sich die Stockscreener-App
2.34
3.31%
-0.08
Handel nachbörslich:
2.41
0.07
+2.99%
Schlusskurs vom Vortag:
$2.42
Offen:
$2.42
24-Stunden-Volumen:
2.05M
Relative Volume:
1.46
Marktkapitalisierung:
$522.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-283.26M
KGV:
-1.2381
EPS:
-1.89
Netto-Cashflow:
$-273.61M
1W Leistung:
-19.03%
1M Leistung:
-44.68%
6M Leistung:
-73.20%
1J Leistung:
-44.29%
1-Tages-Spanne:
$2.31
$2.485
1-Wochen-Bereich:
$2.31
$3.015
52-Wochen-Spanne:
$2.31
$12.00
Sana Biotechnology Inc Stock (SANA) Company Profile
Firmenname
Sana Biotechnology Inc
Sektor
Branche
Telefon
(206) 701-7914
Adresse
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Vergleichen Sie SANA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SANA | 2.34 | 522.45M | 0 | -283.26M | -273.61M | -1.89 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-08-14 | Eingeleitet | TD Cowen | Market Perform |
| 2023-05-02 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-03-01 | Eingeleitet | BofA Securities | Buy |
| 2021-03-01 | Eingeleitet | Goldman | Neutral |
| 2021-03-01 | Eingeleitet | JP Morgan | Neutral |
| 2021-03-01 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.SANA - PR Newswire
Sana Biotechnology (NASDAQ:SANA) Reaches New 1-Year LowHere's Why - MarketBeat
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
10 Stocks Jeff Bezos Is Buying | Investing - U.S News & World Report Money
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot - Investing.com India
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner - Quantisnow
Sana Biotechnology, Inc. (NASDAQ:SANA) Holdings Lowered by Baillie Gifford & Co. - MarketBeat
Sana Biotechnology stock hits 52-week low at $2.75 By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotechnology stock hits 52-week low at $2.75 - Investing.com India
Sana Biotech sustains stock target with Buy rating on Q3 earnings - Investing.com Nigeria
Analyst keeps Buy on Sana Biotechnology, adjusts outlook as blood cancer competition rises - Investing.com Canada
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot By Investing.com - Investing.com Canada
Sana Biotechnology (NASDAQ:SANA) Hits New 1-Year LowWhat's Next? - MarketBeat
Sana Biotechnology Inc Still Hasn’t Convinced Analysts? - Stocks Register
HC Wainwright Reaffirms "Buy" Rating for Sana Biotechnology (NASDAQ:SANA) - MarketBeat
Sana Biotechnology downgraded to Market Perform from Outperform at JMP Securities - MSN
Sana Biotechnology, Inc. Reports Q3 2024 Financial Results - TipRanks
Sana: Q3 Earnings Snapshot - The Washington Post
Sana Biotechnology Inc. (SANA) Quarterly 10-Q Report - Quartzy
Earnings Flash (SANA) SANA BIOTECHNOLOGY Reports Q3 Loss $-0.27 Per Share - Marketscreener.com
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times
HC Wainwright Issues Positive Estimate for SANA Earnings - Defense World
HC Wainwright Issues Optimistic Forecast for SANA Earnings - MarketBeat
Sana Biotechnology refocuses on autoimmune and diabetes therapies By Investing.com - Investing.com Australia
Sana lowered to market perform by JMP over data uncertainty - MSN
Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low on Analyst Downgrade - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $8.00 at HC Wainwright - MarketBeat
Sana Biotechnology stock hits 52-week low at $3.05 - Investing.com
Sana to lay off staff, deepen autoimmune focus in latest retrenchment - BioPharma Dive
500: Something went wrong - Investing.com UK
Sana Biotechnology stock hits 52-week low at $3.05 By Investing.com - Investing.com Canada
JMP Securities Downgrades Sana Biotechnology (NASDAQ:SANA) to Market Perform - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotechnology refocuses on autoimmune and diabetes therapies - Investing.com
Sana Biotechnology Announces Increased Focus on Type 1 - GlobeNewswire
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.6%Here's Why - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Up 7.7%Still a Buy? - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.4%What's Next? - MarketBeat
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Why Sana Biotechnology, Inc. (SANA) is the Penny Stock with the Biggest Upside Potential According to Analysts - Insider Monkey
Biotech stock tumbles after unexplained 1,446% gain - MSN
Sana Biotechnology Inc (SANA) looking to reclaim success with recent performance - SETE News
Sana Biotechnology Inc [SANA] Stock sold by Insider Mulligan Richard for $0.61 million - Knox Daily
Market Insights: Sana Biotechnology Inc (SANA)’s Notable Gain of 4.18, Closing at 3.99 - The Dwinnex
Sana Biotechnology Inc (SANA)’s stock price in review: A technical analysis - US Post News
Sana Biotechnology, Inc. (SANA): Jeff Bezos Is Buying This Stock Now - Insider Monkey
Renaissance Technologies LLC Decreases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Finanzdaten der Sana Biotechnology Inc-Aktie (SANA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):